Welcome to the latest edition of the  BioLines Weekender
2019 has come in like a lion F rom  co-hosting the
Wine with BIO Friends Reception and  attending the 
J.P. Morgan Healthcare Conference and Biotech Showcase in San Francisco to testifying before the Assembly Health and Senior Services Committee in opposition to a proposed Prescription Drug Review Commission, attending the Governor's State of the State presentation and submitting comments to the Centers for Medicare and Medicaid Services on a proposal to bring step therapy to Medicare beneficiaries, the BioNJ Team has been on the move.

In preparation for BioNJ's 26th Annual Dinner Meeting and Innovation Celebration, taking place on February 7, we've been busy making sure everything is perfect for our guests -- from the food to the presentations, awards and special surprises. We've been on the road interviewing thought leaders throughout New Jersey for our video in honor of Dr. William Hait, the 2019 Dr. Sol J. Barer Award for Vision, Innovation and Leadership honoree. ( Click here to register.)

And meanwhile, earlier this week, we announced that the New Jersey Department of Banking and Insurance approved BioNJ's Member-only Health Benefits Planoffering a cost-effective health benefit solution to the New Jersey life sciences ecosystem. (Click here for FAQs.)

We look forward to seeing you on February 7!

Because Patients Can't Wait®,
The BioNJ Team
BioNJ Calendar

BioNJ's Annual Dinner Meeting & Innovation Celebration
Hilton East Brunswick, East Brunswick, NJ
February 7, 2019
Webinar: BioNJ Health Benefits Plan
February 20, 2019

Putting Patients First: The Value of Medical Innovation
Brought to You by Celgene Corporation

Medical innovation enables longer and better quality lives and, in turn, reduces the costs of healthcare. Share with our community how your medical innovation is improving lives and impacting healthcare costs. Send us your Patient and related stories to BioNJ@BioNJ.org. Plus, click here for valuable tools and resources on the Value of Medical Innovation.

Discussions about costs are important. Too often patients struggle to afford the medicines they need. Our industry is committed to working with policymakers on solutions that enhance the competitive marketplace, lower costs for patients and promote continued medical innovation.

BioNJ in the News

(OP-ED) How many times did you hear, "Here's to good health" this holiday season? As we age, we become increasingly aware of the importance of "good health." That's one reason so many people felt hopeful about a recent announcement by the Food and Drug Administration (FDA) that the agency approved more than 50 new molecular entities in 2018, including 16 approvals for cancer drugs, as well as drugs for HIV, Hepatitis C and rare diseases. Twenty of the new drugs came from companies with a footprint in New Jersey.

NJ Company News

Ever proud of our ecosystem, we are pleased to share our New Jersey Company News. Be sure to click on the article titles below to read the full release.

Newark-based BioNJ Member Rafael Pharmaceuticals, Inc. announced that the European Medicines Agency (EMA) has granted orphan drug designation to devimistat (CPI-613®), the Company's lead Altered Metabolism Directed (AMD) drug candidate, for the treatment of older patients (≥ 60 years) with relapsed or refractory Acute Myeloid Leukemia (AML). AML is a hematologic malignancy characterized by the accumulation of clonal myeloid progenitor cells ("blasts") in the blood or bone marrow. 

Cranbury-based BioNJ Member   Amicus Therapeutics  announced the initiation of a Phase 1/2 clinical study to evaluate the safety and efficacy of a single intrathecal administration of adeno-associated virus serotype 9 AAV9-CLN3 (AAV9-CLN3) gene therapy in children with CLN3 Batten disease. Batten disease is the common name for a broad class of rare, fatal, inherited disorders of the nervous system also known as neuronal ceroid lipofuscinoses, or NCLs. 

Bridgewater-based BioNJ Member   Sanofi  announced that the  U.S. Food and Drug Administration  has approved the expanded use of Adacel (Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis (Tdap) Vaccine Adsorbed) to include repeat vaccination to help protect against tetanus, diphtheria and pertussis. According to Sanofi, it is the first and only Tdap vaccine in the U.S. approved for a repeat dose in people 10 through 64 years of age, eight years or more after the first vaccination. 

The New England Journal of Medicine (NEJM) published positive results of the Phase 3 trial of Bridgewater-based BioNJ Member Sanofi's  Cablivi® (caplacizumab) in adults with acquired thrombotic thrombocytopenic purpura (aTTP). aTTP is a rare, life-threatening autoimmune blood disorder characterized by extensive clot formation in small blood vessels throughout the body, leading to severe thrombocytopenia (very low platelet count), microangiopathic hemolytic anemia (loss of red blood cells through destruction), ischemia (restricted blood supply to parts of the body) and widespread organ damage, especially in the brain and heart.

The Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) voted eight to eight on the question of whether the overall benefits of Zynquista™ (sotagliflozin), developed by Bridgewater-based BioNJ MemberSanofi and Lexicon, outweighed the risks to support approval. Sotagliflozin is an investigational oral dual SGLT1 and SGLT2 inhibitor under regulatory review as an adjunct to insulin for the treatment of adults with type 1 diabetes (T1D).

Princeton-based BioNJ Member   Otsuka America, Inc. and Click Therapeutics, Inc., announce that the companies have signed a collaboration agreement to develop and commercialize a prescription digital therapeutic for treatment of Major Depressive Disorder (MDD), with the intent to address unmet medical needs among this patient population and to improve outcomes. This collaboration will leverage Click's demonstrated ability to discover and validate a software application and deploy it commercially, with Otsuka's expertise in developing approved prescription therapies for patients with serious mental illnesses, including Otsuka's established development and commercialization capabilities. 

Parsippany-based BioNJ Member The Medicines Company announced that the 5th review of un-blinded safety and efficacy data by the Independent Data Monitoring Committee (IDMC) for inclisiran Phase 3 trials has been completed. The IDMC has once again recommended that the trials continue as designed and conducted, without modification.

Princeton-based BioNJ Member   Agile Therapeutics, Inc. announced that  it received final meeting minutes from its  December 11, 2018  meeting with the U.S. Food and Drug Administration's Division of Bone , Reproductive, and Urologic Products ("DBRUP"). The company met with DBRUP to discuss the design of a comparative wear study between Twirla ®  and Xulane ®  (the "comparative wear study") as suggested by FDA's  Office of New Drugs  ("OND") in its decision on the company's previously announced formal dispute resolution request. 

Princeton-based BioNJ Member   Bristol-Myers Squibb Company  announced that the European Commission has approved the combination of Opdivo  (nivolumab) 3 mg/kg plus Yervoy  (ipilimumab) 1 mg/kg ("low-dose") for the first-line treatment of patients with intermediate- and poor-risk advanced renal cell carcinoma (RCC). This decision represents the first approval of an Immuno-Oncology (I-O) combination therapy for patients with this type of cancer in the European Union.

Bridgewater-based BioNJ Member   Allergan plc  announced positive 3-month topline results from the second pivotal clinical trial of Bimatoprost SR, a first-in-class sustained-release, biodegradable implant for the reduction of IOP in patients with open-angle glaucoma or ocular hypertension. Positive results from the first Phase 3 trial were reported in  June 2018 . Bimatoprost SR is designed to lower IOP for at least 4 months, achieving clinical goals while freeing patients from daily eye drop regimens. 

Kenilworth-based BioNJ Member   Merck & Co. announced the first presentation of results from KEYNOTE-181, a Phase 3 trial investigating KEYTRUDA, Merck's anti-PD-1 therapy, as monotherapy for the second-line treatment of advanced or metastatic esophageal or esophagogastric junction carcinoma. In this pivotal study, KEYTRUDA met a primary endpoint by significantly improving overall survival (OS) in patients with squamous cell carcinoma or adenocarcinoma who progressed after standard therapy and whose tumors expressed PD-L1 (Combined Positive Score [CPS] ≥10), with a 31 percent reduction in the risk of death compared to chemotherapy (paclitaxel, docetaxel or irinotecan).

Kenilworth-based BioNJ Member   Merck announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA, Merck's anti-PD-1 therapy, for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma (MCC), based on the results of the Cancer Immunotherapy Trials Network (CITN)'s CITN-09/KEYNOTE-017 trial. 

Titusville-based BioNJ Member  The Janssen Pharmaceutical Companies of Johnson & Johnson announced the submission of a Group Type II Variation Application to the European Medicines Agency (EMA) seeking approval of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active ulcerative colitis (UC). Ustekinumab is a human monoclonal antibody that targets the interleukin (IL)-12 and IL-23 cytokines, which are believed to play an important role in the immune and inflammatory responses seen in immune-mediated diseases, such as UC and Crohn's disease.

Princeton -based Sandoz Inc., a division of BioNJ Member  Novartisand Pear Therapeutics, Inc., announced the U.S. commercial launch of reSET-O(TM) for patients with Opioid Use Disorder (OUD). reSET-O, cleared by the U.S. Food and Drug Administration (FDA) in December, is immediately available. The reSET-O prescription digital therapeutic (PDT) is a 12-week cognitive behavioral therapy intended to be used in addition to outpatient treatment. 

Princeton -based Sandoz Inc., a division of BioNJ Member  Novartisannounced the US market introduction of SYMJEPI™ (epinephrine) 0.3 mg Injection for the emergency treatment of allergic reactions (Type 1), including anaphylaxis. Sandoz is launching this medicine as an affordable, single-dose, pre-filled syringe alternative to epinephrine auto-injectors. SYMJEPI will be rolled out through a phased launch, first in the institutional setting -- an established channel where Sandoz Inc. has significant experience and knowledge -- followed by introduction into the retail market.

Touted by East Hanover -based BioNJ Member  Novartis chief Vas Narasimhan as a potential blockbuster, the drugmaker's sickle cell disease (SCD) drug has secured the FDA's breakthrough therapy designation for its ability to prevent debilitatingly painful vaso-occlusive crisis for patients affected by the group of inherited red blood cell disorders that typically afflict those of African ancestry.

BioNJ Member Pfizer Inc., with offices in Madison, announced that the U.S. Food and Drug Administration (FDA) accepted for filing the company's New Drug Applications (NDAs) for tafamidis for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM). Pfizer has submitted two NDAs based on two forms of tafamidis: meglumine salt and free acid. Tafamidis is the only product to complete a Phase 3 trial evaluating its efficacy, safety, and tolerability in patients with ATTR-CM, a rare, fatal and underdiagnosed condition.

BioNJ Member Pfizer Inc., with offices in Madison, announced the initiation of a Phase 2b/3 clinical trial for its oral JAK3 inhibitor, PF-06651600, for the treatment of patients with moderate to severe alopecia areata, a chronic autoimmune skin disease that causes hair loss on the scalp, face, or body and currently has no approved therapies.

Bridgewater-based BioNJ Member Eli Lilly and Company  announced a definitive agreement for Lilly to acquire  Loxo Oncology  for  $235.00  per share in cash, or approximately  $8.0 billion Loxo Oncology  is a biopharmaceutical company focused on the development and commercialization of highly selective medicines for patients with genomically defined cancers. The acquisition would be the largest and latest in a series of transactions Lilly has conducted to broaden its cancer treatment efforts with externally sourced opportunities for first-in-class and best-in-class therapies. 

Basking Ridge-based BioNJ Member  Ipsen announced that abobotulinumtoxinA (Dysport®) and its recombinant botulinum toxins pipeline are the subject of 50 posters at the 2019 TOXINS International Conference. Results are presented from basic science (in vivoin vitroex vivoin silico), to clinical (Phase I to IV) and patients and caregivers surveys. Data highlights include further differentiation of Dysport® in the treatment of spasticity and movement disorders, results from the first in-human study of a recombinant neurotoxin (rBoNT-E), real life data (ULIS-III) as well as a survey with insights from patients and caregivers on the burden of spasticity (Carenity).

Bedminster-based BioNJ Member Matinas BioPharma Holdings, Inc. announced they have signed an agreement with an undisclosed top global pharmaceutical company aimed to evaluate synergistic effects of Matinas' lipid-nano-crystal ("LNC") platform delivery technology with their partner's nucleic acid polymer technology. Formulations will be developed using Matinas' LNC delivery technology which enables the development of a wide range of difficult-to-deliver molecules.

Princeton-based BioNJ Member Evotec AG announced that its strategic alliance with BioNJ Member Celgene Corporation has reached another important scientific achievement, resulting in Celgene designating a programme and triggering a payment of $ 14.0 m to Evotec. The payment was received by year-end 2018. This scientific achievement was the advancement of a programme into the lead optimisation stage developed from Evotec's compound library using its induced pluripotent stem cell ("iPSC") based screening platform.

BeiGene, Ltd., with offices in  Ridgefield Park,  announced that the  U.S. Food and Drug Administration  ( FDA ) has granted Breakthrough Therapy designation for its investigational Bruton's tyrosine kinase (BTK) inhibitor, zanubrutinib, for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.

Woodcliff Lake-based  Eisai Co., Ltd. and Purdue Pharma L.P. announced that a new drug application has been submitted to the U.S. Food and Drug Administration (FDA) for lemborexant, an investigational agent for sleep-wake regulation, seeking approval for the treatment of insomnia, a sleep-wake disorder. This application was based on the results of two pivotal Phase 3 clinical studies in patients with insomnia, SUNRISE 1 (Study 304) and SUNRISE 2 (Study 303), enrolling approximately 2,000 patients, as well as important safety studies, including assessment of postural stability after middle-of-the-night awakening and a next-morning driving study.

New Brunswick-based Hemispherx Biopharma, Inc. announced Roswell Park Comprehensive Cancer Center Institutional Review Board approval and shipment of Ampligen to start an oncology clinical study combining its dsRNA TLR3 agonist Ampligen with Merck's Keytruda (pembrolizumab) in Metastatic Triple Negative Breast Cancer. The study will enroll at least six participants and be conducted by Drs. Mateusz Opyrchal and Pawel Kalinski at Roswell Park.

Bedminster-based  Aerie Pharmaceuticals, Inc.  announced the topline results of its pilot Phase 2 study of netarsudil ophthalmic solution in a Japanese-American population. The study was designed in accordance with the requirements of Japan's PMDA (Pharmaceuticals and  Medical Devices Agency ) to support the potential regulatory submission of netarsudil ophthalmic solution in  Japan . Netarsudil ophthalmic solution 0.02% is known by the name Rhopressa ®  in  the United States , where it is currently marketed.

Basking Ridge-based  Daiichi Sankyo Company and UCB Japan Co., Ltd announce that VIMPAT ®  Tablets 50 mg and 100 mg (generic name: lacosamide) has been approved, adding a new dosage and administration regimen for pediatric patients (4 years and older) to the indication of the "partial onset seizures of epilepsy patients with or without secondary generalization".  

Basking Ridge-based  Daiichi Sankyo Company announced the receipt of marketing approval in Japan for MINNEBROTM Tablets 1.25 mg, 2.5 mg and 5 mg (generic name: esaxerenone; hereafter, the drug) for the treatment of hypertension. MINNEBROTM is one of the compounds identified during the research collaboration with Exelixis, Inc., and has subsequently been developed by Daiichi Sankyo. 

Basking Ridge-based  Daiichi Sankyo Company announced the receipt of marketing approval in Japan for Tarlige® Tablets 2.5 mg, 5 mg, 10 mg, 15 mg (generic name: mirogabalin besylate; hereafter, the drug) for the treatment of peripheral neuropathic pain (PNP). This drug, an α2δ ligand created by Daiichi Sankyo, was submitted for marketing approval in February 2018 on the basis of the results of a Phase 3 clinical trial in patients with diabetic peripheral neuropathic pain (DPNP)  and a Phase 3 clinical trial in patients with postherpetic neuralgia (PHN).

Florham Park-based Cellectar Biosciences announced median overall survival (mOS) in Cohorts 1-4 of the company's ongoing Phase 1 clinical trial evaluating CLR 131 for the treatment of relapsed/refractory (R/R) multiple myeloma (MM). The results showed mOS of 22.0 months among 15 patients, all of whom were heavily pretreated, averaging five prior lines of systemic therapy. Each patient in Cohorts 1-4 of this dose-escalation study received a single 30-minute infusion of CLR 131.

Warren-based  Bellerophon Therapeutics, Inc.  announced top-line results from Cohort 1 of the Company's ongoing Phase 2b randomized, double-blind, placebo-controlled clinical study (iNO-PF) evaluating INOpulse® in patients with Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD). 

Athenex , Inc., with offices in Cranford, announced that target enrollment of 360 patients in the Oraxol Phase III clinical trial in metastatic breast cancer has been achieved on schedule.  Athenex  also reaffirms that top line data from the study is expected to be available in mid-2019.

Princeton-based Luye Pharma has announced it has entered an agreement with AstraZeneca China, the terms of which grant AstraZeneca China exclusive rights to promote Luye Pharma's Xuezhikang Capsules in mainland China. This is the first time that a multinational pharmaceutical company has gained exclusive authorization in China to promote an innovative drug independently developed by a Chinese pharmaceutical company.

Cranford-based Citius Pharmaceuticals, Inc. reported that a definitive license agreement has been reached with MD Anderson Cancer Center to develop and commercialize a novel approach to reducing post-operative infections associated with surgical implants. The initial product called "Mino-Wrap", or CITI 101, is a liquefying gel-based wrap containing minocycline and rifampin for reducing tissue expander (TE) infections following breast reconstructive surgeries. 

Takeda Pharmaceutical Company Limited, with offices in East Windsor, announced the completion of its acquisition of Shire plc, becoming a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan. Takeda now has an attractive, expanded geographic footprint and leading position in Japan and the U.S., bringing its highly-innovative medicines to approximately 80 countries/regions with dedicated employees worldwide. 

Freehold-based Avalon GloboCare Corp. announced that the company and its wholly owned subsidiary, Avactis Biosciences, have entered into a joint venture and exclusive license agreement with Arbele Limited to co-develop next generation, transposon-based Chimeric Antigen Receptor (CAR)-T and CAR-Natural Killer (NK) cellular therapies. These unique CAR vector constructs are non-virally engineered, possessing multiple therapeutic targets as well as unique "safety-switch" mechanisms.  

ALK, with offices in Bedminster,  announced top-line results from a Phase III paediatric clinical trial of its sublingual allergy immunotherapy (SLIT) tablet for the treatment of ragweed-induced allergic rhinitis. The trial, which lasted three years and involved 1,022 participants in North America and Europe, was a Phase III, randomised, placebo-controlled trial to study the efficacy and safety of ALK's ragweed SLIT-tablet in children aged 5 to 17 with a history of ragweed-induced allergic rhinitis (also known as hay fever).

Westfield-based Acquist Therapeutics, Inc. announced that the U.S. Patent Office has issued two new patents covering the Acquist investigational drug library. These patents cover compounds intended for treatment of patients with NASH (nonalcoholic steatohepatitis), gout, and other illnesses. 

Little Silver-based Additive Orthopaedics, LLC. announces that is has received FDA 510(k) clearance for its Patient Specific 3D Printed Locking Lattice Plates indicated for alignment, stabilization and fusion of fractures, osteotomies and arthrodesis of small bones such as the foot and ankle.    

Princeton-based Vyome Therapeutics has raised $22 million (about Rs 154 crore) in a fresh round of funding led by Mumbai-based venture growth fund Iron Pillar to expand its team and further invest in research and development. Existing investors Perceptive Advisors, Romulus Capital and Kalaari Capital also participated in this round. 

Berkely Heights-based CorMedix announced the topline results of the interim analysis of the Company's Phase 3 LOCK-IT-100 study for Neutrolin® as a catheter lock solution in hemodialysis patients.  As previously announced, the study was terminated at the recommendation of the independent Data Safety Monitoring Board (DSMB) after the interim analysis was completed in July 2018, because efficacy had been demonstrated and the pre-specified level of statistical significance had been achieved.  The DSMB reported that there were no safety concerns

People in the News

South Plainfield-based BioNJ Member  PTC Therapeutics, Inc.  announced the promotion of Dr. Mark Pykett  to Chief Scientific Officer and Dr. Neil Almstead  to Chief Technical Operations Officer. "Achievement of our long-term strategy requires accelerating our research engine with our small molecule and gene therapy platforms as well as fostering our manufacturing expertise to focus on supplying the needs of our advancing gene therapy franchise," said Stuart W. Peltz , Ph.D., Chief Executive Officer of  PTC Therapeutics .

Rutherford-based BioNJ Member  Cancer Genetics Inc.  announced it has appointed William Finger its new Executive Vice President, Precision Medicine and Biopharma Solutions, effective immediately. He  will be responsible for developing and overseeing the company's precision medicine and biopharma, and clinical trial business unit. Dr. Finger, who has more than 25 years of experience in the life sciences, diagnostics and lab services industry, most recently served as managing director, precision medicine and diagnostics for Kineticos. 

Warren-based  Aquestive Therapeutics Inc.  announced it has appointed Gary H. Slatko as Senior Vice President, Chief Medical Officer. Dr.  Slatko will be responsible for heading clinical and medical affairs for the company. He will report directly to CEO Keith J. Kendall. Prior to Aquestive, Dr. Slatko was a director in the Office of Medication Error Prevention and Risk Management at the U.S. Food and Drug Administration. Before that, he was Chief Medical Officer of ParagonRx. 

Bridgewater-based  Amneal Pharmaceuticals Inc.  announced it has named David A. Buchen its new Senior Vice President, Chief Legal Officer and Corporate Secretary. Mr.  Buchen, who will report directly to CEO and President Robert Stewart, will be responsible for leading the company's global legal, intellectual property and corporate compliance functions. Mr. Buchen, who has more than 25 years of experience in the pharmaceutical industry, most recently served as a consultant to various manufacturing, marketing and distribution companies. 

Navitas Life Sciences , a Princeton business of TAKE Solutions, has named a veteran pharmaceutical executive as its new Global Head of Clinical. Steve Galen, who has held leadership roles with companies including Covance, PRA, InVentiv Health and Syneos Health, will join the clinical, regulatory and safety solutions company's Princeton office. Mr. Galen has more than 20 years of pharma and contract research organization experience.

Vascular Therapies Inc. announced it has appointed a new CEO.  John McDermott, who has more than 30 years of experience in vascular technologies, will head the Cresskill-based company. Dr. Sriram Iyer, Founder of Vascular Therapies, has done an excellent job leading the company since inception and will continue as its Chief Scientific Officer," Bob Croce, Chairman of the Board of Directors of Vascular Therapies, Inc, said.

ALK, with offices in Bedminster,  announced the appointment of Christian G. Houghton as its new Head of Product Supply, which includes all global manufacturing activities. Mr. Houghton has been with ALK for 25 years and was previously Head of Chemistry, Manufacturing and Controls (CMC) and selected manufacturing sites.

Institution and Education News

Rebecca Lubot has been named Director of the  Governor's STEM Scholars program, the  Research & Development Council of New Jersey announced.  Established in 2013, the Governor's STEM Scholars program is a public-private partnership among the Governor's Office, the  New Jersey Department of Education , the  Office of the Secretary of Higher Education  and the members of the R&D Council of New Jersey.

Read the latest news on research, treatment, prevention and education from the State's National Cancer Institute-designated Comprehensive Cancer Center in Cancer Connection Monthly.

Scientists at Rutgers and universities in Russia, Poland and England have solved a nearly 30-year mystery -- how the molecular machinery works in an enzyme that makes a potent antibiotic. The findings, which appear in the journal Molecular Cell, provide the tools to design new antibiotics, anticancer drugs and other therapeutics.

Cooper University Health Care announced that Dr. Anthony Mazzarelli and Kevin O'Dowd, will become Co-Chief Executive Officers effective June 1. Dr. Adrienne Kirby, Executive Chairman and CEO, will retire on June 1. Dr.  Mazzarelli and Mr. O'Dowd have been serving as Co-Presidents since March 2018. Dr. Kirby joined Cooper in 2012 and has led Cooper through its transformation into a major academic health system, including the development of its MD Anderson partnership.

Jean-Pierre Issa, M.D., a world-renowned expert in the epigenetics of cancer and director of Temple University's Fels Institute for Cancer Research and Molecular Biology, will join the Coriell Institute for Medical Research as its new President and Chief Executive Officer, Coriell's Board of Trustees Chairman Robert Kiep, III, announced today. His first day is scheduled for February 28, 2019.

Funding News

A new report prepared by  Econsult Solutions Inc., and praised by former Gov. Jim Florio in the introduction, touts the positive impact of investments on social determinants of health in Camden.  ESI's 44-page report, submitted to the  Rowan University / Rutgers-Camden  Board of Governors, highlights a number of changes to the city since 2006, including investments in public safety, education, neighborhood and physical environment, health and health care and economic development. .

The  New Jersey Business and Industry Association unveiled 12 metrics the state would need to excel in if it were to become the so-called "State of Innovation," as outlined in Gov. Phil Murphy's October economic outline.  The NJBIA, in its Indicators of Innovation study, compiled an "innovation score," taking into account 12 factors broken into three areas: capital, talent and business.

The NJBAC is a state agency offering free and confidential assistance to help your business grow. As a "one-stop shop," NJBAC can help businesses of all sizes and types to manage the state's regulatory processes, boost exports, gain access to financial resources where applicable and tackle other obstacles along the way. You can download the NJBAC guide by clicking here or contact their business advocates at 1-800 JERSEY 7. 
Special Programs from Our Partners for BioNJ Members

January 23, 2019 | Princeton Innovation Center BioLabs

Steve Sun grew GENEWIZ from a two-person biotech startup to an international operation employing more than 1000 people across 12 facilities around the world. Genewiz was acquired in September 2018 for $450 MILLION. Steve will share the GENEWIZ story, followed by Q&A. Click here to register. 

February 1, 2019 | New Brunswick

Join us for the largest recruitment event targeting Rutgers Business School programs, including New Brunswick and Newark business students. We anticipate close to 100 employers in attendance recruiting for leadership programs, internships, co-ops and full-time opportunities. This event is hosted by the  Office of Career Management-New Brunswick .

February 20, 2019 | Newark, DE

The Science & Technology Career Fair connects employers with exemplary candidates in search of new career opportunities. Organizations looking to fill full-time, part-time and internship roles are encouraged to exhibit. This event traditionally attracts over 350 scientists and technologists with a broad range of educational and technical expertise. For more information, visit https://delawarebio.org/events/career-fair/.

June 3-6, 2019 | Philadelphia Convention Center

The BIO International Convention is hosted by the Biotechnology Innovation Organization (BIO), which represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. The key benefits of attending the 2019 BIO International Convention are access to global biotech and pharma leaders via BIO One-on-One Partnering, exposure to industry thought leaders with over 500 education sessions at your fingertips and unparalleled networking opportunities with 16,000+ attendees from 67 countries. 

BIO is offering BioNJ Members the opportunity to lock in a significant discount on two premier registration packages for the 2019 BIO International Convention and Convention Access & Partnering. Click here for details. DEADLINE TODAY.